文献速递甲状腺疾病

甲状腺激素代谢物3-碘甲状腺乙酸具有抗惊厥和神经保护作用

Anticonvulsant and Neuroprotective Effects of the Thyroid Hormone Metabolite 3-Iodothyroacetic Acid.
PubMed 文献 · Thyroid · 2018-01-01

该研究在小鼠戊四氮惊厥模型及大鼠海马器官型切片中评估了TA1的抗惊厥和神经保护作用。TA1(7和11 μg/kg)显著减少惊厥小鼠数量并延长发作潜伏期,在切片中减少KA诱导的细胞死亡,均通过激活PI3K/AKT通路实现。组胺H1受体拮抗剂吡拉明可消除TA1的上述效应。

要点

  • TA1(7和11 μg/kg)可减少戊四氮诱导的惊厥小鼠数量并延长发作潜伏期。
  • TA1通过激活PI3K/AKT通路在体内外发挥神经保护作用。
  • 吡拉明(H1受体拮抗剂)可消除TA1的抗惊厥和神经保护效应。

核心结论

  • TA1在体内和体外均具有抗惊厥活性和神经保护作用。
  • TA1的作用可能通过组胺H1受体介导,并涉及PI3K/AKT通路激活。

研究设计与样本

  • CD1雄性小鼠腹腔注射生理盐水或TA1(4、7、11或33 μg/kg)后皮下注射90 mg/kg戊四氮。
  • 大鼠海马器官型切片暴露于5 μM红藻氨酸(KA)±0.01-10 μM TA1或10 μM T3、TRIAC、T1AM、T0AM或TA0。
  • 急性海马切片CA3神经元采用膜片钳记录评估TA1对KA诱导电流的影响。

主要发现

  • TA1(7和11 μg/kg)显著减少惊厥小鼠数量并延长发作潜伏期,恢复戊四氮诱导的海马c-fos水平降低。
  • TA1激活PI3K/AKT并降低GSK-3β活性。
  • 在大鼠器官型海马切片中,TA1通过激活PI3K/AKT和增加GSK-3β磷酸化减少KA诱导的细胞死亡。
  • T3及其他T3代谢物(TRIAC、T1AM、T0AM、TA0)也产生对抗KA毒性的保护作用。
  • TA1不与KA受体相互作用;吡拉明(10 mg/kg或1 μM)预处理可消除TA1的抗惊厥和神经保护效应。

临床怎么用

  • TA1及其类似代谢物可能为惊厥相关疾病提供新的治疗思路,但需进一步临床研究验证。

局限性

  • 研究仅基于小鼠和大鼠离体切片模型,尚未在人体中验证。
  • TA1的具体分子靶点和上游信号机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 3-Iodothyroacetic acid (TA1) is among the thyroid hormone (T3) metabolites that can acutely modify behavior in mice. This study aimed to investigate whether TA1 is also able to reduce neuron hyper-excitability and protect from excitotoxic damage. METHODS: CD1 male mice were treated intraperitoneally with saline solution or TA1 (4, 7, 11, or 33 μg/kg) before receiving 90 mg/kg pentylenetrazole subcutaneously. The following parameters were measured: latency to first seizure onset, number of mice experiencing seizures, hippocampal levels of c-fos, and PI3K/AKT activation levels. Organotypic hippocampal slices were exposed to vehicle or to 5 μM kainic acid (KA) in the absence or presence of 0.01-10 μM TA1. In another set of experiments, slices were exposed to vehicle or 5 μM KA in the absence or presence of 10 μM T3, 3,5,3'-triiodothyroacetic acid (TRIAC), T1AM, thyronamine (T0AM), or thyroacetic acid (TA0). Neuronal cell death was measured fluorimetically. The ability of TA1 and T3, TRIAC, T1AM, T0A, and TA0 to activate the PI3K/AKT cascade was evaluated by Western blot. The effect of TA1 on KA-induced currents in CA3 neurons was evaluated by patch clamp recordings on acute hippocampal slices. RESULTS: TA1 (7 and 11 μg/kg) significantly reduced the number of mice showing convulsions and increased their latency of onset, restored pentylenetrazole-induced reduction of hippocampal c-fos levels, activated the PI3K/AKT, and reduced GSK-3β activity. In rat organotypic hippocampal slices, TA1 reduced KA-induced cell death by activating the PI3K/AKT cascade and increasing GSK-3β phosphorylation levels. Protection against KA toxicity was also exerted by T3 and other T3 metabolites studied. TA1 did not interact at KA receptors. Both the anticonvulsant and neuroprotective effects of TA1 were abolished by pretreating mice or organotypic hippocampal slices with pyrilamine, an histamine type 1 receptor antagonist (10 mg/kg or 1 μM, respectively). CONCLUSIONS: TA1 exerts anticonvulsant activity and is neuroprotective in vivo and in vitro. These findings extend the current knowledge on the pharmacological profile of TA1 and indicate possible novel clinical use for this T3 metabolite.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Laurino A, Landucci E, Resta F, et al. Anticonvulsant and Neuroprotective Effects of the Thyroid Hormone Metabolite 3-Iodothyroacetic Acid. Thyroid. 2018. PMID: 30129879. doi:10.1089/thy.2017.0506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。